CSIMarket
 


Enzon Pharmaceuticals inc   (ENZN)
Other Ticker:  
 
 

ENZN's Net Cash Flow Growth by Quarter and Year

Enzon Pharmaceuticals Inc 's Net Cash Flow results by quarter and year




ENZN Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.46 0.79 -0.25 42.83
III Quarter September -0.43 0.06 -0.30 -0.60
II Quarter June 1.11 -0.64 0.00 0.77
I Quarter March -1.11 -0.21 0.05 -0.30
FY   0.03 0.00 -0.50 42.70



ENZN Net Cash Flow fourth quarter 2023 Y/Y Growth Comment
Enzon Pharmaceuticals Inc reported fall in Net Cash Flow in the fourth quarter 2023 by -42.41% to $ 0.46 millions, from the same quarter in 2022.
Despite modest results in the fourth quarter 2023, contraction in Enzon Pharmaceuticals Inc 's Net Cash Flow appears to be smaller than Company's recent average decline.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Net Cash Flow growth. While Enzon Pharmaceuticals Inc ' s Net Cash Flow drop of -42.41% ranks overall at the positon no. 327 in the fourth quarter 2023.




ENZN Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -42.41 % - - -
III Quarter September - - - -
II Quarter June - - - -73.81 %
I Quarter March - - - -
FY   3.0023997515803E+16 % - - -

Financial Statements
Enzon Pharmaceuticals Inc 's fourth quarter 2023 Net Cash Flow $ 0.46 millions ENZN's Income Statement
Enzon Pharmaceuticals Inc 's fourth quarter 2022 Net Cash Flow $ 0.79 millions Quarterly ENZN's Income Statement
New: More ENZN's historic Net Cash Flow Growth >>


ENZN Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 1216.67 % - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - -99.88 % -
FY (Year on Year)   3.0023997515803E+16 % - - -




Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #31
Overall #327

Net Cash Flow Y/Y Growth Statistics
High Average Low
-101.17 % -151.01 % -258.5 %
(Dec 31 2021)   (June 30. 2016)
Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #31
Overall #327
Net Cash Flow Y/Y Growth Statistics
High Average Low
-101.17 % -151.01 % -258.5 %
(Dec 31 2021)   (June 30. 2016)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Enzon Pharmaceuticals Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZN's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2023Seasonal Enzon Pharmaceuticals inc in the influence net cash outflow of $ 0.46 millionsSeasonal influence seem to have added to Enzon Pharmaceuticals inc 's return to profitability, as ENZN postNet Cash Flow of $ 0.46 millions in the IV. Quarter 2023 coming of net cash outflow-0.43 millions in the third quarter. Enzon Pharmaceuticals inc announced in the IV. Quarter 2023 Net Cash Flow of $ 0.46 millions compare to net cash outflow recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Enzon Pharmaceuticals inc achieved highest sequential Net Cash Flow growth. While Enzon Pharmaceuticals Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENZN's IV. Quarter Q/Q Net Cash Flow Comment
IV. Quarter 2023Cyclical Enzon Pharmaceuticals inc in the influence net cash outflow of $ 0.46 millionsCyclical influence seem to have added to Enzon Pharmaceuticals inc 's rebound to profitability, as ENZN postNet Cash Flow of $ 0.46 millions in the IV. Quarter 2023 emerging from net cash outflow-0.43 millions in the third quarter. Enzon Pharmaceuticals inc announced in the IV. Quarter 2023 Net Cash Flow of $ 0.46 millions compare to net cash outflow recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Enzon Pharmaceuticals inc achieved highest sequential Net Cash Flow growth. While Enzon Pharmaceuticals Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Enzon Pharmaceuticals Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Cash Flow 12 Months Ending $ 0.03 $ 0.36 $ 0.85 $ -0.89 $ 0.00
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) -91.76 % -57.02 % - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 327 # 408 # 0 # 0 # 0




Cumulative Net Cash Flow growth Comment


Enzon Pharmaceuticals inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
-101.17 %
-151.01 %
-258.5 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 31
S&P 500 # 327
Cumulative Net Cash Flow growth Comment


Enzon Pharmaceuticals inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
-101.17 %
-151.01 %
-258.5 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 31
S&P 500 # 327




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
ENZN's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for ENZN's Competitors
Net Cash Flow Growth for Enzon Pharmaceuticals Inc 's Suppliers
Net Cash Flow Growth for ENZN's Customers

You may also want to know
ENZN's Annual Growth Rates ENZN's Profitability Ratios ENZN's Asset Turnover Ratio ENZN's Dividend Growth
ENZN's Roe ENZN's Valuation Ratios ENZN's Financial Strength Ratios ENZN's Dividend Payout Ratio
ENZN's Roa ENZN's Inventory Turnover Ratio ENZN's Growth Rates ENZN's Dividend Comparisons



Companies with similar Net Cash Flow drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2023
Astrazeneca Plc-5.29%$ -5.287 millions
Lipocine Inc -6.98%$ -6.984 millions
Caredx Inc -14.62%$ -14.617 millions
Sophia Genetics Sa-16.41%$ -16.406 millions
Xencor Inc-17.78%$ -17.780 millions
Kronos Bio Inc -20.78%$ -20.784 millions
Earth Science Tech Inc -21.38%$ -21.381 millions
Hookipa Pharma inc -22.19%$ -22.193 millions
Anaptysbio Inc -24.22%$ -24.222 millions
Koru Medical Systems Inc-26.57%$ -26.570 millions
Abbott Laboratories-35.07%$ -35.069 millions
Lantheus Holdings Inc -37.16%$ -37.161 millions
Alcon inc -37.78%$ -37.778 millions
Inflarx N v -38.04%$ -38.037 millions
Novartis Ag-39.41%$ -39.413 millions
Argenx se-40.00%$ -40.005 millions
Gh Research Plc-40.04%$ -40.040 millions
Bright Minds Biosciences Inc -41.15%$ -41.154 millions
Enzon Pharmaceuticals inc -42.33%$ -42.332 millions
Myriad Genetics Inc -44.65%$ -44.653 millions
Elutia inc -46.46%$ -46.456 millions
Gilead Sciences Inc -46.70%$ -46.704 millions
Koninklijke Philips Nv-49.11%$ -49.110 millions
Avidity Biosciences Inc -49.45%$ -49.449 millions
Proqr Therapeutics N v -49.46%$ -49.460 millions
Protalix Biotherapeutics inc -49.52%$ -49.523 millions
Xeris Biopharma Holdings Inc -49.99%$ -49.994 millions
Altair International Corp -52.34%$ -52.344 millions
Macrogenics Inc -55.57%$ -55.574 millions
Atricure Inc -59.98%$ -59.983 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com